SciSparc Ltd. filings document foreign private issuer disclosures for a clinical-stage pharmaceutical company with ordinary shares listed on Nasdaq. The record includes Form 6-K reports and Form 20-F references covering NeuroThera Labs patent and clinical-regulatory updates, cannabinoid-based drug programs, the MUSE endoscopic-system IP portfolio, and hemp seed oil-based product operations.
The company’s SEC materials also describe capital-structure and financing matters, including convertible promissory notes, warrants, resale registration statements, Form F-3 and Form S-8 incorporation, shareholder meeting approvals, reverse-share-split mechanics, Nasdaq continued-listing compliance, governance matters and risk-related disclosure categories.
SciSparc Ltd. agreed with L.I.A. Pure Capital Ltd. to issue up to $10,000,000 in convertible promissory notes. At the November 3, 2026 initial closing, SciSparc issued a note with $3,000,000 principal for a $2,550,000 purchase price. Beginning January 1, 2027, SciSparc may request additional notes, subject to the agreement’s conditions, for up to $3,000,000 in each subsequent three-month period.
Each note includes a warrant for no additional consideration, with 200% coverage of the maximum shares issuable upon conversion. The initial warrant covers up to 11,457,269 ordinary shares at $0.5237 per share and is exercisable upon issuance through November 2, 2029. The holder may convert at the lower of $0.5237 or 85% of the lowest daily volume weighted average price over 20 consecutive trading days, subject to a $0.11592 floor and 4.99% beneficial-ownership limit. Notes bear 4% annual interest, rising to 14% upon an Event of Default. The initial note is to be repaid in ten equal monthly installments beginning May 3, 2028, unless repaid earlier at SciSparc’s option or extended at the Holder’s option. SciSparc intends to use net note proceeds and net cash proceeds from warrant exercises for working capital and general corporate purposes.
SciSparc Ltd. entered into an inducement letter agreement with L.I.A Pure Capital Ltd. under which the holder agreed to cash-exercise existing warrants to purchase up to 405,728 ordinary shares at a reduced exercise price of $1.0 per share, compared with the existing $4.929 exercise price.
SciSparc expects approximately $405,728 in aggregate gross proceeds. Closing is expected on or about October 27, 2026, subject to customary closing conditions; the company expects to use net proceeds for working capital and general corporate purposes. Resale of the underlying ordinary shares was previously registered.
SciSparc Ltd. said its majority-owned subsidiary NeuroThera Labs completed manufacturing investigational SCI-110 and obtained batch release certification from a European Qualified Person, authorizing shipment of trial material for its FDA-approved Phase IIb study in adults with Tourette syndrome. The study is being conducted at three sites: Yale Child Study Center at Yale School of Medicine in New Haven, Connecticut; Hannover Medical School in Hanover, Germany; and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. All three sites completed initiation activities and are prepared to receive supplies.
NeuroThera says shipments are expected in the near term and the study is advancing toward patient enrollment. The study evaluates SCI-110’s efficacy, safety and tolerability. The drug candidate combines dronabinol and palmitoylethanolamide in a single oral dosage form.
On October 15, 2026, SciSparc Ltd. entered into an inducement letter with note holder L.I.A Pure Capital Ltd., offering the holder the opportunity to convert the note’s outstanding principal and accrued interest into ordinary shares at a $1.50 per-share conversion price. The outstanding amount was $2,023,039.21 as of October 15, 2026. No additional cash payment is required from the holder, and SciSparc will receive no cash proceeds from the conversion. Closing is expected on or about October 16, 2026, subject to conditions and contingencies described as customary in similar U.S. agreements. Resale of the shares issuable upon conversion has been registered under SciSparc’s effective Form F-3 registration statement.
SciSparc Ltd. (SPRC) announced a planned strategic shift toward Agentic AI-powered technologies, including cybersecurity and finance. The company intends to evaluate technologies, companies and business opportunities across the Agentic AI ecosystem, following its July 27, 2026 announcement that it would target the market and its August 26, 2026 announcement establishing a Scientific Advisory Board for AI and Cybersecurity.
SciSparc describes Agentic AI as systems designed to autonomously plan and execute tasks to achieve defined objectives. It says it will continue evaluating opportunities, while cautioning that these efforts may not result in a transaction, commercial agreement or revenue-generating activity. The company also describes its existing operations through NeuroThera as clinical-stage pharmaceutical development, with drug programs based on THC and/or non-psychoactive CBD.
SciSparc Ltd. said its majority-owned subsidiary NeuroThera Labs Inc. reported that its majority-owned subsidiary CliniQuantum Ltd. used a GPU-accelerated quantum-simulation platform to search 7,331,162,245 possible three-gene combinations in a clinical gene-expression dataset. Using a predefined minimum correlation threshold, the algorithm identified approximately 22.2 million correlated gene triplets.
On a machine with 64 cores, a single NVIDIA T4 GPU completed the analysis in approximately 0.5 hours, compared with approximately 8.4 hours using 64 vCPUs, producing the same qualifying triplet results. The reported computational acceleration was approximately 16.8-fold. The dataset comprised 11 patients and 3,531 gene-expression features. The benchmark evaluated computational performance only; it did not evaluate or establish the clinical validity, predictive value or potential utility of the gene combinations.
SciSparc Ltd. reported first-half 2026 revenue of $284,000, compared with $461,000 in the prior-year period. Net loss was $6.051 million, versus $9.412 million, while operating loss was $4.887 million, versus $2.713 million. Research and development expenses rose to $1.575 million from $938,000, and general and administrative expenses rose to $3.198 million from $2.109 million.
Operating cash use was $3.561 million, compared with $1.861 million. As of June 30, 2026, cash, cash equivalents and restricted deposits totaled $4.458 million. SciSparc said its cash and cash equivalents were not sufficient to fund planned operations for at least a year beyond the financial statements’ filing date, and that these factors raise substantial doubt about its ability to continue as a going concern.
On June 3, subsidiary NeuroThera acquired 54.01% of CliniQuantum for 56,600,000 NeuroThera shares, with additional earn-out payments of up to $2.5 million contingent on milestones. On August 18, SciSparc invested C$2.7 million, or 50% of the gross proceeds, in NeuroThera’s C$5.4 million financing. SciSparc held approximately 44.6% of NeuroThera after the financing.
SciSparc announced that its subsidiary NeuroThera highlighted three published U.S. patent applications from its ongoing collaboration with Clearmind. The applications cover combinations of LSD, ketamine and ibogaine with N-acylethanolamines, including NeuroThera’s proprietary PEA technology.
The applications describe potential uses for mental health disorders, including depression and PTSD, as well as pain and substance use disorders. The collaboration also includes a previously announced U.S. patent application covering MDMA combined with N-acylethanolamines for potential treatment of PTSD, anxiety and eating disorders.
SciSparc Ltd. (SPRC), through its majority-owned subsidiary NeuroThera Labs, reports operational progress in two key clinical programs. Enrollment in the SCI-210 autism spectrum disorder trial has reached 26 children toward a planned total of 60 in a double-blind, randomized, placebo-controlled study at Soroka Medical Center in Israel, with each participant receiving treatment over 20 weeks. SCI-210 combines cannabidiol (CBD) with CannAmide, a Palmitoylethanolamide-based formulation, and is being evaluated against CBD monotherapy using endpoints such as the ABC-C questionnaire and CGI-I assessment.
NeuroThera is also pursuing FDA Orphan Drug Designation for SCI-110, its cannabinoid-based candidate for adults with Tourette Syndrome, and has engaged U.S. government and public affairs firm RK Strategies to support this regulatory path and U.S. stakeholder engagement. SCI-110, now in a Phase IIb program across three academic centers in the United States, Germany and Israel, previously showed an average 21% tic reduction in a Phase IIa study, providing early clinical support for further development.